Health Care • Biotechnology: Pharmaceutical Preparations
$165.00 ▼ -9.00
(-5.17%)
MKT CAP: $22.10B • VOL: 7.06M
52W L $163 52W H $480
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$139
MEDIAN
$185
MEAN
$188
HIGH
$224
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ALNY TAPE
ALNY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $199.65 | $189.75 | 2025-02-14 | $150.15 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $207.90 | $194.70 | 2025-02-06 | $155.10 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $188.10 | $181.50 | 2025-01-29 | $158.40 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $168.30 | — | 2025-01-17 | $161.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $145.20 | $156.75 | 2025-01-09 | $146.85 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $196.35 | $171.60 | 2024-12-18 | $143.55 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $160.05 | $166.65 | 2024-12-04 | $153.45 | -4.3% | 48% | C |